Results 11 to 20 of about 21,847 (205)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK [PDF]

Frontiers in Cell and Developmental Biology, 2021
Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s description of agammaglobulinemia set the stage for ultimately understanding key signaling steps emanating from
Kueffer, Lauren E., Joseph, Raji E., Andreotti, Amy H.   +2 more
openaire   +3 more sources

Kvantitatív drámaelemzés és az idő

Digitális Bölcsészet, 2023
A kvantitatív drámaelemzés legtöbbször a színművek egészére vonatkozó, statikus mérőszámokból indul ki, továbbá kevés figyelmet fordít az e mérőszámokkal leírt szerkezeti tulajdonságok történeti változásaira. A tanulmányban ezért korábbi eredményeinket,
Botond Szemes, Magyar Magyar
doaj   +1 more source

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.

PLoS ONE, 2023
Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y Lin, Amy H Andreotti
doaj   +2 more sources

Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector

Molecular Therapy: Methods & Clinical Development, 2021
X-linked agammaglobulinemia (XLA) is an immune disorder caused by mutations in Bruton’s tyrosine kinase (BTK). BTK is expressed in B and myeloid cells, and its deficiency results in a lack of mature B cells and protective antibodies.
Brenda J. Seymour, Swati Singh, Hannah M. Certo, Karen Sommer, Blythe D. Sather, Socheath Khim, Courtnee Clough, Malika Hale, Joseph Pangallo, Byoung Y. Ryu, Iram F. Khan, Jennifer E. Adair, David J. Rawlings   +12 more
doaj   +1 more source

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK

eLife, 2020
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph, Neha Amatya, D Bruce Fulton, John R Engen, Thomas E Wales, Amy Andreotti   +5 more
doaj   +1 more source

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Journal of Hematology & Oncology, 2021
B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu, Hanning Tang, Jiazhu Wu, Jianyong Li, Yi Miao   +4 more
doaj   +1 more source

Bruton’s Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae

Journal of Innate Immunity, 2022
Humans with dysfunctional Bruton’s tyrosine kinase (Btk) are highly susceptible to bacterial infections. Compelling evidence indicates that Btk is essential for B cell-mediated immunity, whereas its role in myeloid cell-mediated immunity against ...
Zhe Liu, Alexander P.N.A. De Porto, Regina De Beer, Joris J.T.H. Roelofs, Onno J. De Boer, Sandrine Florquin, Cornelis Van’t Veer, Rudi W. Hendriks, Tom Van der Poll, Alex F. De Vos   +9 more
doaj   +1 more source

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

Journal of Experimental Pharmacology, 2021
Francesco Paolo Tambaro,1 Danilo De Novellis,1,2 William G Wierda3 1Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy; 2Department of Precision Medicine ...
Tambaro FP, De Novellis D, Wierda WG
doaj  

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

Biomarker Research, 2022
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang, Xueying Lu, Jianyong Li, Yi Miao   +3 more
doaj   +1 more source

Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases

Pharmaceuticals, 2023
Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases.
Asim Najmi, Neelaveni Thangavel, Anugeetha Thacheril Mohanan, Marwa Qadri, Mohammed Albratty, Safeena Eranhiyil Ashraf, Safaa Fathy Saleh, Maryam Nayeem, Syam Mohan   +8 more
doaj   +1 more source